Previous 10 | Next 10 |
Fuwei Films (NASDAQ: FFHL ) +66% on Q1 results . More news on: Fuwei Films (Holdings) Co., Ltd., Translate Bio, Inc., Recon Technology, Ltd., Stocks on the move, , Read more ...
Co-primary endpoints met with response rates of 74.5% for dysmenorrhea (menstrual pain) and 58.5% for non-menstrual pelvic pain (p-values < 0.0001) Women receiving relugolix combination therapy, on average, had a 73.3% reduction on the Numerical Rating Scale for dysmenorrhea from...
LONDON and NEW YORK, June 22, 2020 (GLOBE NEWSWIRE) -- Sumitovant Biopharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review, the New Drug Application (NDA) submitted by Myovant Sciences (NYSE: MYOV), for once-daily, oral rel...
Gainers: APYX +35.1% . ALLO +4.3% . NRZ +3.4% . MYOV +2.9% . CMCL +2.8% . More news on: Apyx Medical Corporation, Allogene Therapeutics, Inc., New Residential Investment Corp., Stocks on the move, , Read more ...
BASEL, Switzerland, June 22, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it will host a webcast and conference call to discuss top-line results from the Phase 3 SPIRIT 1 study of onc...
Priority Review status expected to accelerate review, with a target FDA action date of December 20, 2020 BASEL, Switzerland, June 22, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced tha...
Are These 2 Best Health Care Stocks On Your Watchlist This Month? Health care stocks have been some of the best-performing stocks since the market bottomed out in March. With a lot of coronavirus developments in play, this sector is racing to come up with a vaccine or treatment. The world ...
Overview Urovant Sciences (NASDAQ: UROV ) is a clinical stage biopharmaceutical company focused on the development and commercialization of its lead product candidate, vibegron, an oral, once-daily, small molecule beta-3 agonist, for the treatment of overactive bladder (OAB), OAB in men...
NEW YORK and LONDON , June 1, 2020 /PRNewswire/ -- Sumitovant Biopharma Ltd. announced today that Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, and one of five healthcare companies in the Sumitovant family of companies, has su...
Gainers: Cemtrex (NASDAQ: CETX ) +209% . More news on: Cemtrex, Inc., Digital Ally, Inc., Allied Esports Entertainment Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / October 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myovant Sciences, Ltd. ("Myovant" or "the Company") (NYSE:MYOV). Investors who purchased Myovant securities are encouraged to obtain additional infor...
Third fiscal quarter 2022 total revenue of $100.2 million ; including net product revenue of $61.4 million Net product revenue from U.S. sales of ORGOVYX ® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume ...
MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences PR Newswire ...